Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Build a Chinese platform and become a global pharmaceutical market——Hongqi Pharmaceutical participated in the 17th World Pharmaceutical Raw Materials China Exhibition
Category:
Company News
Author:
Source:
Add time:2017-07-20 09:31
Summary:On June 20, 2017, the 17th World Pharmaceutical Raw Materials China Exhibition was grandly opened at Shanghai New International Exhibition Center. According to the official statistics of the conference, the exhibition area of this exhibition totaled 170,000 square meters, 2,800 domestic and overseas companies participated in the exhibition, and more than 50,000 professional buyers from more than 120 countries and regions attended the exhibition.
On June 20, 2017, the 17th World Pharmaceutical Raw Materials China Exhibition was grandly opened at Shanghai New International Exhibition Center. According to the official statistics of the conference, the exhibition area of this exhibition totaled 170,000 square meters, 2,800 domestic and overseas companies participated in the exhibition, and more than 50,000 professional buyers from more than 120 countries and regions attended the exhibition. The World Pharmaceutical Raw Materials China Exhibition has become the best platform for Chinese companies to invest, trade, communicate and cooperate with the world.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as Fosun Pharma) and its 7 companies participated in the exhibition. Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as Hongqi Pharmaceutical), as a wholly-owned subsidiary of Fosun Pharma, follows Fosun Pharma Participate together.
As a leading domestic tuberculosis drug company, Hongqi Pharmaceutical has attracted the attention of Chinese and foreign customers at this exhibition, attracting professionals in the tuberculosis field from Africa, Southeast Asia and other countries to the booth for consultation, inspection, and business negotiation. The initial cooperation intention has been reached. Good publicity effect. This exhibition is of great significance to Hongqi Pharmaceutical. It not only has an in-depth understanding of the international pharmaceutical development situation, but also understands the international pharmaceutical policy, which has played a significant role in the company's expansion of the Asian and African markets.
From the 1980s to the present, Hongqi Pharmaceutical has always been at the frontline of anti-tuberculosis drug research and development, and has bravely assumed the responsibility and mission of a pharmaceutical company. It has 3 national first-class new drugs, 1 third-class new drugs, and 2 core independent intellectual property rights. At present, Hongqi Pharmaceutical has become the country's main anti-tuberculosis drug R&D and production base, making important contributions to China's tuberculosis control and becoming an indispensable brand in the minds of doctors and patients. The Hongqi brand has become China's leading brand in the field of anti-tuberculosis. R&D, marketing, and talents drive Hongqi Pharmaceuticals to focus on R&D and marketing in the domestic tuberculosis drug market, constantly challenging new heights.
